Literature DB >> 20160206

Frontotemporal dementia and pharmacologic interventions.

Edward D Kaye1, Ana Petrovic-Poljak, Nicolaas P L G Verhoeff, Morris Freedman.   

Abstract

Frontotemporal lobar degeneration is comprised of three syndromes: frontotemporal dementia (FTD), semantic dementia, and progressive nonfluent aphasia, with FTD being the most prevalent. FTD is characterized predominantly by character change and disordered social conduct. A variety of pathologies may underlie these syndromes, yet it is the location of the pathology rather than the type that dictates the clinical features of the disease. Several medications have been investigated to measure efficacy of treatment in FTD, often with mixed results. The authors review these findings and comment on future directions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160206     DOI: 10.1176/jnp.2010.22.1.19

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  10 in total

Review 1.  Therapy and clinical trials in frontotemporal dementia: past, present, and future.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  J Neurochem       Date:  2016-06-15       Impact factor: 5.372

Review 2.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

3.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

4.  Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study.

Authors:  Tiffany W Chow; David Fam; Ariel Graff-Guerrero; Nicolaas P G Verhoeff; David F Tang-Wai; Mario Masellis; Sandra E Black; Alan A Wilson; Sylvain Houle; Bruce G Pollock
Journal:  Int J Geriatr Psychiatry       Date:  2012-06-04       Impact factor: 3.485

5.  Frontotemporal dementia and primary progressive aphasia: an update.

Authors:  Howard S Kirshner
Journal:  Curr Neurol Neurosci Rep       Date:  2010-11       Impact factor: 5.081

6.  Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial.

Authors:  Pan Li; Wei Quan; Yu-Ying Zhou; Yan Wang; Hui-Hong Zhang; Shuai Liu
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447

Review 7.  Mechanisms of granulin deficiency: lessons from cellular and animal models.

Authors:  Gernot Kleinberger; Anja Capell; Christian Haass; Christine Van Broeckhoven
Journal:  Mol Neurobiol       Date:  2012-12-13       Impact factor: 5.590

8.  Compulsive carnival song whistling following cardiac arrest: a case study.

Authors:  A Rosaura Polak; Jasper W van der Paardt; Martijn Figee; Nienke Vulink; Pelle de Koning; Miranda Olff; Damiaan Denys
Journal:  BMC Psychiatry       Date:  2012-07-03       Impact factor: 3.630

9.  Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.

Authors:  Tiffany W Chow; Ariel Graff-Guerrero; Nicolaas Plg Verhoeff; Malcolm A Binns; David F Tang-Wai; Morris Freedman; Mario Masellis; Sandra E Black; Alan A Wilson; Sylvain Houle; Bruce G Pollock
Journal:  Neuropsychiatr Dis Treat       Date:  2011-07-13       Impact factor: 2.570

Review 10.  Primary progressive aphasia: a clinical approach.

Authors:  Charles R Marshall; Chris J D Hardy; Anna Volkmer; Lucy L Russell; Rebecca L Bond; Phillip D Fletcher; Camilla N Clark; Catherine J Mummery; Jonathan M Schott; Martin N Rossor; Nick C Fox; Sebastian J Crutch; Jonathan D Rohrer; Jason D Warren
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.